ReviewPharmacological research2019
Straight to the heart: Pleiotropic antiarrhythmic actions of oral anticoagulants.
Review in Pharmacological research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 26 citations in OpenAlex.
- Cellular and molecular cross-talk in atrial fibrillation: The role of non-cardiomyocytes in creating an arrhythmogenic substrate.The Journal of physiology · 2026Review
- Thrombin receptor PAR4 cross-activates the tyrosine kinase c-met in atrial cardiomyocytes.Naunyn-Schmiedeberg's archives of pharmacology · 2025Article
- The thrombin receptor PAR4 supports visceral adipose tissue inflammation.Naunyn-Schmiedeberg's archives of pharmacology · 2024Article
- Pathophysiology and clinical relevance of atrial myopathy.Basic research in cardiology · 2024Review
- Prophylactic rivaroxaban in the early post-discharge period reduces the rates of hospitalization for atrial fibrillation and incidence of sudden cardiac death during long-term follow-up in hospitalized COVID-19 survivors.Frontiers in pharmacology · 2023Article
- Interaction of Cardiovascular Nonmodifiable Risk Factors, Comorbidities and Comedications With Ischemia/Reperfusion Injury and Cardioprotection by Pharmacological Treatments and Ischemic Conditioning.Pharmacological reviews · 2023Review
- Direct oral anticoagulation and severe obesity - One size fits all?International journal of cardiology. Heart & vasculature · 2021Article
- Stroke prevention of atrial fibrillation: Improving geographic under-use of contemporary antithrombotic approaches remains a challenge.International journal of cardiology. Heart & vasculature · 2021Article
- Natural history of COVID-19 and current knowledge on treatment therapeutic options.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2020Review
- Anticoagulant and antiarrhythmic effects of heparin in the treatment of COVID-19 patients.Journal of thrombosis and haemostasis : JTH · 2020Article
- Breaking bad: Higher risk of osteoporosis with vitamin K antagonists compared to direct oral anticoagulants in patients with atrial fibrillation.International journal of cardiology. Heart & vasculature · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Mechanistic understanding of atrial fibrillation (AF) pathophysiology and the complex bidirectional relationship with thromboembolic risk remains limited. Oral anticoagulation is a mainstay of AF management. An emerging concept is that anticoagulants may themselves have potential pleiotropic disease-modifying effects. We here review the available evidence for hemostasis-independent actions of the oral anticoagulants on electrical and structural remodeling, and the inflammatory component of the vulnerable substrate.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.